Optibiotix Health Share Discussion Threads

[rayrac] 17/6/2021 15:14

OPTI has made massive losses yet again, and would be 2p today, if it couldnt dwell on sbtx, of which none of you shareholders will ever see value from anyway

Our cash to hand is far exceeded by costs

Unquote

Revenue isn’t even covered by expenses!…let alone mention of profits which which they reckon is covered by the value of sbtx on the books…which we all know, is a very dodgy place to be and shouldn’t be called profits, just a dodgy asset.

[valuetracker] 17/6/2021 15:14

Key support broken following woeful results. I expect this to drift to the 20p support level.

[kreature] 17/6/2021 15:04

might be helpful

[kreature] 17/6/2021 14:59

will there be a podcast to spin and suggest everything that I don't understand in the rns?

[sentiment riles] 17/6/2021 12:50

dont give it slimb anyway. Try a milk machine. Opti might be releasing one soon

[manc10] 17/6/2021 12:35

the only thing i have thats fat is my wallet looool

[sentiment riles] 17/6/2021 12:32

you are on slimb years. And now slim porridge?

is it not working? Or were you 155 stone?

[manc10] 17/6/2021 12:31

anyway off out to get some slim expert porrige wonderful

[manc10] 17/6/2021 12:30

Group sales for the 12 months ended 31 December 2020 (prior period: 13 months ended 31 December 2019) grew by 104% to £1,523,247 (2019: £744,883) while other administrative expenses reduced by 27% to £1,616,069 (2019: £2,204,217). Despite the challenges presented by the global COVID-19 pandemic, both the Functional Fibres and Probiotic divisions achieved profitability at the EBITDA level, after losses in the prior 13 month period.



The Company received an additional £746,751 during the year from the partial disposal of its holding in SkinBioTherapeutics plc ('SBTX'), which is not included in the Group revenue figures. As a result of the change in the Company's shareholding in SBTX, it is now treated as an investment rather than an associate and the change in the value in the Company's shareholding during the financial year will in future be reflected in the Group accounts. The increase in the value of the SBTX holding of £7,120,962 during the year results in a Group net profit for the year of £5,801,867 (2019: net loss £2,368,362).



The Group's financial position remains strong, with total cash on the balance sheet at the year-end increasing by 90% to £864,680 (2019: £455,608). Post period, the Company sold £900,936 SBTX shares in March 2021 to further strengthen its balance sheet.

[sentiment riles] 17/6/2021 12:26

At least cenkos gave us an escape this morning. Good for something anyway

An unrelated broker would have opened it -20%

[sentiment riles] 17/6/2021 12:19

Can you imagine if cenkos wasnt a paid agent in sbtx and opti?

What a disaster day for both

[sentiment riles] 17/6/2021 12:15

All in the share price bud. Even syme is trading better than opti today. i guess syme rns, not deemed as bad as opti's

[sentiment riles] 17/6/2021 12:08

Yes manc

Translated:

OPTI has made massive losses yet again, and would be 2p today, if it couldnt dwell on sbtx, of which none of you shareholders will ever see value from anyway

Our cash to hand is far exceeded by costs

"We will address this soon"

[manc10] 17/6/2021 12:06

Group sales for the 12 months ended 31 December 2020 (prior period: 13 months ended 31 December 2019) grew by 104% to £1,523,247 (2019: £744,883) while other administrative expenses reduced by 27% to £1,616,069 (2019: £2,204,217). Despite the challenges presented by the global COVID-19 pandemic, both the Functional Fibres and Probiotic divisions achieved profitability at the EBITDA level, after losses in the prior 13 month period.



The Company received an additional £746,751 during the year from the partial disposal of its holding in SkinBioTherapeutics plc ('SBTX'), which is not included in the Group revenue figures. As a result of the change in the Company's shareholding in SBTX, it is now treated as an investment rather than an associate and the change in the value in the Company's shareholding during the financial year will in future be reflected in the Group accounts. The increase in the value of the SBTX holding of £7,120,962 during the year results in a Group net profit for the year of £5,801,867 (2019: net loss £2,368,362).



The Group's financial position remains strong, with total cash on the balance sheet at the year-end increasing by 90% to £864,680 (2019: £455,608). Post period, the Company sold £900,936 SBTX shares in March 2021 to further strengthen its balance sheet.

[sentiment riles] 17/6/2021 12:04

need to just get in at right time Manc


[...]
— StayOnTop (@Stayontop123On)



OPTi right time will be sub 23p somewhere. Probably 7-9p

[john henry] 17/6/2021 11:59

Someuwin if you strip out SBTX which has been and is by far the best product in the OPTI portfolio you get a valuation of around £15M imho theres at least a potential 10% upside for a trade.
Agreed as an investment its been very very poor.No share price growth for nearly 6 years.

[manc10] 17/6/2021 11:56

any one got a price on syme loooll

[manc10] 17/6/2021 11:55

anybody got a price on sbtx loooooooool

[sentiment riles] 17/6/2021 11:54

manc1017 Jun '21 - 11:53 - 55435 of 55436
0 0 0
llllllllllllloool i know you dont you bought syme lol

.......

exactly Manc :)

[sentiment riles] 17/6/2021 11:54

Due to numbers known

Why cant you focus on audited facts manc, instead of forever chasing numbers only suggested

[manc10] 17/6/2021 11:53

llllllllllllloool i know you dont you bought syme lol